Research reveals GLP-1 and SGLT-2 medications may lower COPD exacerbation risk in diabetes, offering new hope for dual condition management.

GSK (GSK) announced that the China National Medical Products Administration, CNMPA, has accepted for review the new drug application for the ...

The current model for managing chronic obstructive pulmonary disease (COPD) generally considers inhalers from the same therapeutic class to be clinically equivalent.1 When a long-acting muscarinic ...

In a landmark meeting half a century ago, William Briscoe used the term COPD. Since then, the pathophysiology and treatment modalities ... the incidences. The new Global Initiative for Obstructive ...

New Study Shows Promising Results for COPD Treatment Nov. 20, 2024 — A new study shows that a form of vitamin B3 can reduce lung inflammation in COPD patients. The researchers hope it will pave ...

Policy experts say if the federal government cuts Medicaid by 10%, more than 100,000 San Diego County residents could lost ...

Opens in a new tab or window Share on Bluesky ... "This may inform prescribing of glucose-lowering medications among patients with T2D and active COPD," making SGLT2 and GLP-1 drugs preferable ...

"These findings suggest that SGLT-2is and GLP-1 RAs may be preferable to DPP4is when deciding among glucose-lowering medications for patients with T2D and active COPD," the authors write.

There are certain risk factors for COPD, including obesity and having type 2 diabetes. A new study has found that people who have type 2 diabetes who are treated with GLP-1 and SGLT-2 medications ...

Patients with COPD had better inhaler adherence when invited to enroll in a program that lowers cost sharing for maintenance inhalers and offers medication management services, according to results ...

High treatment costs can restrict patient access to the most effective therapies, especially in low- and middle-income countries where healthcare costs are a significant burden. Regulatory Challenges: ...

Fortunately, recent studies have found lung function decline to be decreasing, yet patients are still experiencing frequent exacerbations, which means that current interventions have not been enough.